How should an 'FDA-approved' claim for an exosome product be checked?

The FDA states that exosome products intended to treat disease or conditions in humans require regulatory review and that there are no FDA-approved exosome products. An 'FDA-registered facility,' laboratory manufacture or a device record is not product approval.

This translation has no recorded clinical or medical-language review.

Direct answer

An approval claim requires verification by product name, application number, indication and route.
Facility registration, a manufacturing certificate or a research listing is not clinical product approval.
U.S. status does not determine Turkish authorization; TİTCK and relevant local records must be checked separately.

What FDA documents say

The FDA's 2019 safety notification and consumer alert explicitly state that there are no FDA-approved exosome products in the United States. A 2025 warning letter also addressed claims involving specific products marketed as unapproved drugs and biological products. These documents do not remove the need to check the current product database and direct FDA record.

Misleading look-alike statements

Terms such as 'FDA registered,' 'manufactured in an FDA-registered facility,' 'research grade,' 'patented' or 'IRB reviewed' do not show approval of the exact product for an indication and route. Registration of a clinical study also does not mean the product has been found safe and effective for routine use.

The distinction in Türkiye

U.S. regulatory information may provide an important safety signal, while product classification, authorization or registration, import, storage, intended use and authority to administer in Türkiye require local verification. A general logo or certificate is insufficient when product name, manufacturer, lot, intended route and current status do not match.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

Microneedling for Facial Rejuvenation: A Systematic Review
Foppiani JA et al. · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Evaluating the Effectiveness and Safety of Radiofrequency for Face and Neck Rejuvenation: A Systematic Review
Austin GK, Struble SL, Quatela VC · 2022
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Energy-Based Devices for the Treatment of Facial Skin Conditions in Skin of Color
Sanyal RD, Fabi SG · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling – FDA Safety Communication
U.S. Food and Drug Administration (FDA) · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products
U.S. Food and Drug Administration (FDA) · 2019
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Supreme Rejuvenation, LLC — FDA Warning Letter 700749
U.S. Food and Drug Administration (FDA) · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies
J. C. Flores Rodríguez et al. · 2026
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials
Systematic review authors; Aesthetic Surgery Journal · 2026
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review